Affordable Access

deepdyve-link
Publisher Website

Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer.

Authors
  • Kawaida, Hiromichi1
  • Kono, Hiroshi2
  • Amemiya, Hidetake2
  • Saitou, Ryou2
  • Yamamoto, Atsushi2
  • Hosomura, Naohiro2
  • Watanabe, Mitsuaki2
  • Kimura, Ayako2
  • Furuya, Shinji2
  • Shimizu, Hiroki2
  • Akaike, Hidenori2
  • Kawaguchi, Yoshihiko2
  • Sudo, Makoto2
  • Itakura, Jun2
  • Hayakawa, Hiroshi3
  • Shindo, Hiroko3
  • Takahashi, E I3
  • Takano, Shinichi3
  • Fukasawa, Mitsuharu3
  • Ichikawa, Shintaro4
  • And 2 more
  • 1 First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan [email protected] , (Japan)
  • 2 First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. , (Japan)
  • 3 First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. , (Japan)
  • 4 Department of Radiology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. , (Japan)
Type
Published Article
Journal
Anticancer Research
Publisher
International Institute of Anticancer Research
Publication Date
Nov 01, 2018
Volume
38
Issue
11
Pages
6537–6542
Identifiers
DOI: 10.21873/anticanres.13019
PMID: 30396983
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Nab-paclitaxel plus gemcitabine (nab-P+Gem) is one of most reliable and effective regimens for borderline or unresectable pancreatic cancer (PC). However, the feasibility and clinical benefits of this regimen have never been evaluated for patients with recurrent PC after pancreatectomy. The aim of this study was to investigate the feasibility of combination therapy with nab-paclitaxel plus gemcitabine (nab-P+Gem) for patients with recurrent PC. Twenty-two patients with recurrent PC received an intravenous infusion of nab-P (125 mg/m2) and Gem (1,000 mg/m2) on days 1, 8, and 15 of a 4-week cycle. The primary end-point of this study was completion of the 4 cycles. The secondary end-points were the safety, efficacy, and disease control rate. The treatment completion rate of the 4 cycles was 90.9%. The objective response rate was 13.6% and the disease control rate was 63.6%. The median progression-free survival was 7.2 months. The most common grade 3 or higher hematological toxicity was neutropenia (72.7%). There was no treatment-related death. Furthermore, the chemotherapeutic effects varied with the time of recurrence. Combination nab-P+Gem therapy was well-tolerated and effective in patients with recurrent PC. Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Report this publication

Statistics

Seen <100 times